Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Interferon-beta aids balance and movement in mice with spinocerebellar ataxia 7

10.06.2013
First in vivo study of the treatment for this condition shows significant physical improvement

Paris, France: The group of genetic conditions known as spinocerebellar ataxias currently have no treatment or cure and are always fatal, in the case of affected children at an early age. Symptoms include a progressive lack of co-ordination of gait, and poor co-ordination of hands, speech and eye movements, due to a failure of co-ordination of muscle movements.

Now researchers from France and the US have found a new way of controlling the symptoms and significantly improving the physical condition of animal models of the disease, the annual conference of the European Society of Human Genetics will hear today (Monday June 10).

Dr. Annie Sittler, from the Centre National de la Recherche Scientifique (CNRS), working in the team of Professor Alexis Brice at the research centre Brain and Spinal Cord Institute (CR-ICM), Paris, France described the team's work in the field of polyglutamine disease, a group of neurodegenerative conditions involving abnormal protein conformation. "Accumulation of a polyglutamine-containing protein known as mutant ataxin -7 is responsible for neurotoxicity, neuronal dysfunction, and eventually neuronal death", she explains. "We had previously shown in cells that mutant ataxin-7 was degraded in nuclear bodies, structures found in the nucleus of cells, by a protein known as promyeloctyic leukaemia protein or PML, and that interferon-beta could help with this process and protect against disease."

The researchers used a mouse model of a particular form of spinocerebellar ataxia known as SCA7. The genetically-modified 'knock-in' mice develop the severe type of the disease, similar to the infantile human version, and have a very short lifespan of around 14 weeks. They were injected with mouse interferon-beta three times a week, starting at five weeks of age, just before their first symptoms of disease were due to appear. Investigation of their brains post-mortem showed that the mice who had received the interferon-beta, as opposed to those in the control group, had a reduced load of mutant ataxin-7.

On the physical level, substantial improvements in the interferon-beta treated mice were noticed. "At twelve weeks of age the physical performance of the mice that received the active substance was significantly improved compared to the control group. We gave them a locotronic test, where they have to cross a kind of ladder. This test is used to check motor co-ordination when walking. We also put them through a beam-walking test, which enables us to measure their balance and limb co-ordination. The treated mice did much better in both of these tests", Dr. Sittler will say.

Further proof of the positive effects of interferon-beta came from analysis of the PML nuclear bodies, involved in many cellular processes such as transcriptional regulation and apoptosis. A subset of these nuclear bodies is responsible for regulating the degradation of accumulated misfolded proteins in the cell nucleus. The treated mice had more, and very much larger, PML bodies, and they were present in the Purkinje cells, responsible for motor co-ordination emanating from the cerebellum The researchers further found that these PML bodies were clastosomes, the specialised nuclear bodies involved in the degradation of mutant ataxin-7 and other polyglutamine-containing proteins. "This, together with the physical improvements we saw in the interferon-beta treated mice, was the proof we needed that our findings in the cell could be successfully transferred to living animals", says Dr. Sittler.

"Now that we have found that interferon-beta can slow progression of disease in SCA7 mice, we believe that, after confirmation in another mouse model, it would be merited to test its effects on humans in a clinical trial,", she will say. "Such trials are difficult in rare diseases, since a special design is needed to test a hypothesis on a small number of patients. However, there are a number of other polyglutamine diseases, for example Huntington's, where patient numbers are larger, and the effects of the condition just as devastating. We hope that our results will encourage others to collaborate with us in order that we may be able to pursue our research to the benefit of all those afflicted with spinocerebellar disorders."

Mary Rice | EurekAlert!
Further information:
http://www.eshg.org

More articles from Life Sciences:

nachricht The dense vessel network regulates formation of thrombocytes in the bone marrow
25.07.2017 | Rudolf-Virchow-Zentrum für Experimentelle Biomedizin der Universität Würzburg

nachricht Fungi that evolved to eat wood offer new biomass conversion tool
25.07.2017 | University of Massachusetts at Amherst

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Carbon Nanotubes Turn Electrical Current into Light-emitting Quasi-particles

Strong light-matter coupling in these semiconducting tubes may hold the key to electrically pumped lasers

Light-matter quasi-particles can be generated electrically in semiconducting carbon nanotubes. Material scientists and physicists from Heidelberg University...

Im Focus: Flexible proximity sensor creates smart surfaces

Fraunhofer IPA has developed a proximity sensor made from silicone and carbon nanotubes (CNT) which detects objects and determines their position. The materials and printing process used mean that the sensor is extremely flexible, economical and can be used for large surfaces. Industry and research partners can use and further develop this innovation straight away.

At first glance, the proximity sensor appears to be nothing special: a thin, elastic layer of silicone onto which black square surfaces are printed, but these...

Im Focus: 3-D scanning with water

3-D shape acquisition using water displacement as the shape sensor for the reconstruction of complex objects

A global team of computer scientists and engineers have developed an innovative technique that more completely reconstructs challenging 3D objects. An ancient...

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

NASA mission surfs through waves in space to understand space weather

25.07.2017 | Physics and Astronomy

Strength of tectonic plates may explain shape of the Tibetan Plateau, study finds

25.07.2017 | Earth Sciences

The dense vessel network regulates formation of thrombocytes in the bone marrow

25.07.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>